Clinical ReviewsDual Targeted Therapy for the Management of Inflammatory Bowel DiseaseHaider, Mahnur MD*; Lashner, Bret MD† Author Information *Section of Internal Medicine and Geriatrics, Tulane University, New Orleans, LA †Department of Gastroenterology and Hepatology, Cleveland Clinic, OH The authors declare that they have nothing to disclose. Address correspondence to: Mahnur Haider, MD, Tulane University School of Medicine, 1430 Tulane Avenue, #8016, New Orleans, LA 70112 (e-mail: [email protected]). Journal of Clinical Gastroenterology: September 2021 - Volume 55 - Issue 8 - p 661-666 doi: 10.1097/MCG.0000000000001583 Buy Metrics Abstract The burden of inflammatory bowel disease (IBD) is increasing globally and imposes a high morbidity in patients with IBD. Advances have been made in medical management of IBD with the advent of novel therapies such as the biologics and small molecule drugs (SMDs). However, response to these medications is limited; with only 40% of patients achieving clinical remission at 1 year with a biologic. Hence, medical management of IBD is a rapidly evolving paradigm in which not only are new medications being developed but understanding how, when and in whom to use them is evolving. Dual targeted therapy (DTT), which is the combination of biologics and/or SMDs is an attractive concept as it is theoretically a potent and multidimensional anti-inflammatory treatment strategy. In this review, we present the published literature on the use of DTT and highlight its utility in clinical practice. The majority of studies on DTT are case reports and case series on the combination of dual biologic therapy. From the limited evidence available in patients with IBD, dual biologic therapy may be a safe option for patients with refractory IBD who have failed multiple biologic therapies and to manage extraintestinal manifestation of IBD. There are a handful of reports of combination therapy with a biologic and a SMD in patients with IBD. Further studies and randomized control trials are required to comprehensivretain hereely evaluate the safety and efficacy of DTT in IBD. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.